Modulation

Optical Compute: How the New Age of Computation Seems So Close, and Yet Still So Far Away, Reports IDTechEx

Retrieved on: 
Friday, April 14, 2023
Television, Heart, Electron, Vacuum, Mzi Mahola, OMAC, Graphics processing unit, Modulation, Life, WDM, Electricity, Light, MRR, Photonics, Research, 2D, Silicon, Laser, HPC, CMOS, Workload, Artificial intelligence, Architecture, PIC, Programmable interrupt controller, Mach–Zehnder interferometer, Silicon photonics, Consumer electronics, Information technology, Video game, Printed circuit board, Intel

This law is named after the co-founder of Intel (and recently deceased) Gordon Moore, who posited this doubling in 1965.

Key Points: 
  • This law is named after the co-founder of Intel (and recently deceased) Gordon Moore, who posited this doubling in 1965.
  • An end to Moore's law is not inherently a bad thing or, at least, it wouldn't be if it existed in a vacuum.
  • While this area of silicon photonics is now well-developed, optical compute has been a trickier riddle to solve.
  • IDTechEx's latest report, " Semiconductor Photonic Integrated Circuits 2023-2033 ", answers the major questions, challenges and opportunities faced by photonic integrated circuit technologies.

Optical Compute: How the New Age of Computation Seems So Close, and Yet Still So Far Away, Reports IDTechEx

Retrieved on: 
Friday, April 14, 2023
Television, Heart, Electron, Vacuum, Mzi Mahola, OMAC, Graphics processing unit, Modulation, Life, WDM, Electricity, Light, MRR, Photonics, Research, 2D, Silicon, Laser, HPC, CMOS, Workload, Artificial intelligence, Architecture, PIC, Programmable interrupt controller, Mach–Zehnder interferometer, Silicon photonics, Consumer electronics, Information technology, Video game, Printed circuit board, Intel

This law is named after the co-founder of Intel (and recently deceased) Gordon Moore, who posited this doubling in 1965.

Key Points: 
  • This law is named after the co-founder of Intel (and recently deceased) Gordon Moore, who posited this doubling in 1965.
  • An end to Moore's law is not inherently a bad thing or, at least, it wouldn't be if it existed in a vacuum.
  • While this area of silicon photonics is now well-developed, optical compute has been a trickier riddle to solve.
  • IDTechEx's latest report, " Semiconductor Photonic Integrated Circuits 2023-2033 ", answers the major questions, challenges and opportunities faced by photonic integrated circuit technologies.

InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China

Retrieved on: 
Tuesday, April 4, 2023
Health, Oncology, Clinical Trials, Modulation, ADCC, Tafasitamab, DLBCL, Multiple myeloma, Hook effect, Clinical trial, NHL, Cancer, Bone marrow, SSE, B-cell lymphoma, HKEX, Patient, Synergism, MM, CRBN, Vaccine, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.
  • ICP-490 is developed from InnoCare’s molecular glue platform for the treatment of multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
  • Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, “ICP-490 is a highly potent next generation CRBN Modulator.
  • NHL is the most common hematological malignancy in the world2, ranking among the top 10 common malignant tumors in China.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Thursday, March 23, 2023
Modulation, Psoriatic arthritis, Asthma, Central nervous system, Eosinophilic esophagitis, PD, Quarter, FCAS, NLRP3, G&A, Atopic dermatitis, CAPS, CNS, Ulcerative colitis, Psoriasis, Research and development, ATM, Acquisition, UC, Patient, Administration, TYK2, Discovery Program, Cryopyrin-associated periodic syndrome, Peripheral, Webcast, R, Research, ALS, Safety, Inflammation, Pharmaceutical industry, Cryptocurrency

Fourth Quarter and Full Year 2022 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2022 Financial Results:
    The amounts presented below for the fourth quarter and full year ended December 31, 2022 reflect the financial results of Ventyx Biosciences, Inc. and its two wholly-owned subsidiaries, Oppilan Pharma Limited (Oppilan) and Zomagen Biosciences Ltd. (Zomagen), on a consolidated basis.
  • Research and Development (R&D) expenses: R&D expenses were $30.2 million for the fourth quarter of 2022, compared to $13.8 million for the fourth quarter of 2021.
  • Net loss: Net loss was $35.2 million for the fourth quarter of 2022, compared to $17.8 million for the fourth quarter of 2021.
  • ET to discuss its fourth quarter and full year 2022 financial results and provide a corporate update.

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Retrieved on: 
Monday, January 9, 2023
IND, Disease, Partner (business rank), Echocardiography, PRISM, Clinical trial, Heart, Dialysis, A101, MD, GA, M.A, Degenerative disease, CF, Initiation, University of Nevada, Reno, Biopsy, Interim, NIH, QOL, University, IHC, Cystic fibrosis, Kidney, AMD, Toxic leukoencephalopathy, Intravitreal administration, RNA, Drug discovery, MRI, Choroideremia, Real-time, GMP, Stanford University School of Medicine, Development, Ahus, Fabry disease, Geographic atrophy, FDA, Retinitis pigmentosa, KCCQ, Addition, Atypical hemolytic uremic syndrome, Fabry, Principal, Ophthalmology, VG, Pulmonology, Enzyme replacement therapy, CFTR, DME, Clinical research, Safety, Diabetic retinopathy, ISH, Modulation, Pharmaceutical industry, Vaccine, 3D printing, Medical imaging, Patient

The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.

Key Points: 
  • The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.
  • It is estimated that there are over one million individuals with GA in the United States according to published data.
  • In addition, I’m excited by the potential of 4D-175, the new preclinical product candidate utilizing the same R100 vector.
  • Cardiac clinical endpoint data (MRI, echocardiography, cardiopulmonary exercise testing [CPET] and QOL assessment) from evaluations at baseline and 12 months after treatment were assessed.

Click Therapeutics Shares 2022 Accomplishments and Development Progress in its Prescription Digital Therapeutics Programs

Retrieved on: 
Friday, December 23, 2022
Data Management, Biotechnology, Alternative Medicine, Technology, Health, Pharmaceutical, Oncology, Neurology, Health Technology, Software, Clinical Trials, Chills, The New England Journal of Medicine, Information technology, Multiple sclerosis, Partnership, Boehringer Ingelheim, Neuroscience, Click, Massachusetts Medical Society, FAAN, IP, Food, Irritable bowel syndrome, Therapy, DWA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD, MMS, Research, Rheumatoid arthritis, Smartphone, Probability, Dynamo, Breast, HIV disease progression rates, Diabetic neuropathy, Invention, Digital, R, Disease, Patient, Medicine, Neurology, Data analysis, Intellectual property, Physician, Inflammation, Schizophrenia, Metabolic pathway, Patent, Fibromyalgia, Doctor of Philosophy, Pharmaceutical industry, Medical imaging, Migraine, Modulation

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.

Key Points: 
  • Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.
  • Click’s DiNaMo program develops and evaluates digital mechanisms of action targeted to one or more neural pathways implicated in disease expression.
  • The DiNaMo program was conceptualized, developed, and validated at Click by a multidisciplinary team with backgrounds in neuroscience, serious gaming, medicine, and mobile application development.
  • Click completed enrollment and study assessments for two randomized, controlled, fully decentralized DiNaMo studies in 2022.

Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis

Retrieved on: 
Wednesday, December 7, 2022
Therapy, Investigational New Drug, Thermoregulation, Food, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Human, Patient, Organ dysfunction, Research, Mucus, HIV disease progression rates, FDA, Modulation, Safety, Sionna, Life expectancy, Health, Pharmacokinetics, Cystic fibrosis transmembrane conductance regulator, Mutation, Cystic fibrosis, Risk, Pharmaceutical industry, CFTR

BOSTON, Dec. 7, 2022 /PRNewswire/ -- Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for SION-638, a novel small molecule designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The first subject has been dosed in a Phase 1 study to evaluate the safety and pharmacokinetics of SION-638 in healthy volunteers.

Key Points: 
  • The first subject has been dosed in a Phase 1 study to evaluate the safety and pharmacokinetics of SION-638 in healthy volunteers.
  • "We have achieved an important milestone of advancing SION-638, a first-in-class NBD1 modulator, into a Phase 1 study.
  • The most common mutation in CFTR, F508, causes NBD1 to unfold at body temperature and severely impairs CFTR function.
  • Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF.

WISE Receives FDA Clearance for its WISE Cortical Strip Bringing Neuromonitoring to the Next Level

Retrieved on: 
Thursday, December 1, 2022
Semiconductor, Manufacturing, Biometrics, Nanotechnology, Other Science, Research, Medical Devices, Hardware, Hospitals, Science, Technology, FDA, Biotechnology, Neurology, Surgery, Public Relations, Investor Relations, Health, Communications, Engineering, Electrode, Intra, University, SCS, Multimedia, EUREKA, Spinal cord, Safety, WIN, Brain, Modulation, Clinical neurophysiology, Neurosurgery, Intraoperative neurophysiological monitoring, University of Milan, WISE, BMI, CE, New Frontier, Hyperreflexia, FDA, Medical device, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20221201005070/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221201005070/en/
    The WISE Cortical Strip is the first product receiving FDA clearance within the Companys WISEneuro Monitoring product family.
  • The FDA clearance follows the CE mark already received by the product in May 2021.
  • The WISE Cortical Strip performances have been successfully validated in a multicentric pre-market clinical study in Europe, the WIN study ( NCT03731455 ), that demonstrated safety, performance and usability of the product.
  • As a result, the WISE Cortical Strip is highly ergonomic and conformable to the brain surface.

ROSALIND FRANKLIN UNIVERSITY NEUROSCIENTIST AWARDED $2.36 MILLION TO STUDY POTENTIAL THERAPEUTIC TARGETS FOR ANXIETY DISORDERS

Retrieved on: 
Wednesday, November 30, 2022
Anxiety, Mental health, Doctor of Philosophy, National Institute of Mental Health, Oxytocin, NIMH, Multimedia, Social anxiety disorder, Attention deficit hyperactivity disorder predominantly inattentive, Modulation, Patient, Fear, Hypothalamus, Research, Hypervigilance, Neuroscience, Doctor of Pharmacy, GAD, BNST, Post-traumatic stress disorder, PTSD, RFU, Human, Anxiety disorder, Rosalind Franklin University of Medicine and Science, Medicine, Meat, Pharmaceutical industry

The new award marks the competitive renewal of Dr. Dabrowska's grant, which started in 2017.

Key Points: 
  • The new award marks the competitive renewal of Dr. Dabrowska's grant, which started in 2017.
  • Stress-induced neuropsychiatric disorders such as PTSD are characterized by hypervigilance manifested as constant threat surveillance and disproportionately higher fear reactivity to unpredictable vs. predictable threat signals.
  • The BNST is hyperactive in patients suffering from generalized anxiety disorder (GAD) and PTSD.
  • Social anxiety disorders impact more than 15 million Americans and about six out of every 100 people will have PTSD at some point in their lives.

Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders

Retrieved on: 
Tuesday, November 29, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Modulation, Mental health, ED, Gate, NMDAR, University, NIMH, United States Public Health Service, Physician, Patient, Suicidal ideation, NMDA, Dean, EEG, CNS, Neuropsychiatry, Depression, Neuroscience, Precision medicine, ERP, Suicide, Wilfrid Sellars, MDD, Pharmaceutical industry, Apimostinel

Gate Neurosciences is developing apimostinel to address urgent patient and evolving practice needs for a safe, rapid-acting, in-office treatment of acute depressive disorders such as postpartum and episodic depression, and depression with suicidality.

Key Points: 
  • Gate Neurosciences is developing apimostinel to address urgent patient and evolving practice needs for a safe, rapid-acting, in-office treatment of acute depressive disorders such as postpartum and episodic depression, and depression with suicidality.
  • Apimostinel previously demonstrated proof-of-concept in a Phase 2a MDD study and the ongoing biomarker study aims to further enhance the understanding of dose dynamics using various electroencephalogram (EEG) measures after single and multiple ascending doses in 40 healthy subjects.
  • Gate Neurosciences plans to use results from the EEG biomarker study to further de-risk dose selection in a confirmatory Phase 2b efficacy study of apimostinel planned for initiation in mid-2023.
  • Gate Neurosciences is a precision medicine biotechnology company focused on advancing next-generation CNS treatments that address growing needs in mental health.